Company
Investment-firm
Last deal
Amount
Stage
Date
all rounds
Total amount
Financing round
General
About Company
Industry
Sector :
Subsector :
founded date
founders
Number of employees
Company Type
Last funding type
IPO status
Contacts
location
Contact Email
Phone number
Website URL
Similar Companies1000
Cerecor
Cerecor develops treatments for immunologic, immuno-oncologic, and rare genetic disorders.
Sector
Subsector
Keywords
Location
total rounds
total raised
Effector Therapeutics
Effector is a clinical-stage biopharmaceutical company developing a new class of oncology drugs.
Sector
Subsector
Keywords
Location
total rounds
total raised
Curtana Pharmaceuticals
Curtana is a biopharmaceutical company that develops therapies for aggressive brain cancer.
Sector
Subsector
Keywords
Location
total rounds
total raised
Peloton Therapeutics
Peloton Therapeutics is a biopharmaceutical company developing cancer drugs.
Sector
Subsector
Keywords
Location
total rounds
total raised
Financials
Funding Rounds15
Number of Funding Rounds
Money Raised
Their latest funding was raised on 27.10.2022. Their latest investor Blackstone Credit. Their latest round Post-IPO Equity
Investments1
ClearPoint Neuro
ClearPoint Neuro is a platform neuro company that enables therapy for neuro disorders with pinpoint accuracy.
Sector
Subsector
Keywords
Location
total rounds
total raised
Co-Investors
Investors14
Number of lead investors
Number of investors
Blackstone Credit
GSO Capital Partners is a venture capital firm based in New York that primarily invests in startups in the United States.
Sector
Subsector
Keywords
Location
count Of Investments
count Of Exists
Blackstone Life Sciences
Blackstone Life Sciences (BXLS) provides funding to bring medicines and healthcare technologies to market in the life sciences industry.
Sector
Subsector
Keywords
Location
count Of Investments
CDI Bioscience
CDI Bioscience develops genetic engineering technology to increase bioproduct yield.
Sector
Subsector
Keywords
Location
total rounds
total raised
count Of Investments
Acquisitions3
Censa Pharmaceuticals acquired by PTC Therapeutics
acquirer
date
type
Censa Pharmaceuticals
Censa Pharmaceuticals develops and commercializes therapeutics for (ultra) orphan CNS disorders.
Sector
Subsector
Location
total rounds
total raised
BioElectron Technology Corporation acquired by PTC Therapeutics
acquirer
date
type
price
BioElectron Technology Corporation
BioElectron is a company that develops redox drugs to treat genetic disorders and neurodegenerative diseases.
Sector
Subsector
Location
total rounds
total raised
Agilis Biotherapeutics acquired by PTC Therapeutics
acquirer
date
type
price
Agilis Biotherapeutics
Agilis Biotherapeutics develops DNA-based therapeutics for genetic disorders.
Sector
Subsector
Location
total rounds
total raised
People
Founders2
Stuart Peltz
Stuart Peltz, Ph.D. founded PTC Therapeutics, Inc. in 1998 and has served as Chief Executive Officer and a member of the board of directors since the company's inception. Under his leadership, PTC has grown from a research organization based in the expertise of RNA processes and control to a publically traded company on NASDAQ focused on the discovery, development and commercialization of orally-administered, small-molecule treatments for genetic disorders, oncology and infectious diseases. Stuart Peltz is a recognized scientific leader in RNA biology in the area of post-transcriptional control processes involving mRNA turnover and translation, with more than 30 years of research and over 100 publications in this area. He and his team have shown the important interplay between the different RNA biology events that ultimately control protein production in the cell. He was involved in developing the first biochemical and genetic assays investigating the regulation of mRNA turnover subsequently demonstrating the strong connection between the processes of protein production and mRNA turnover. His work was instrumental in identifying and characterizing components of multiple mRNA decay and translation pathways. These findings have been translated to build novel drug discovery platforms and targets that allow PTC to search for potential new drugs to treat genetic disorders, oncology, and infectious diseases. Stuart Peltz’s development of the nonsense readthrough platform led to the discovery of the first approved drug for Duchenne muscular dystrophy in the European Union. Prior to founding PTC, Stuart Peltz was a Professor in the Department of Molecular Genetics & Microbiology at the Robert Wood Johnson Medical School, Rutgers University. Stuart Peltz has received a number of business and scientific awards. Notably, he was elected as a Fellow of the American Academy for the Advancement of Science in 2010. He received the 2014 Stuart Sol J. Barer Award for Vision Innovation and Leadership and was recognized as PharmaVoice’s 100 Most Inspiring People in 2009. He is a member of the board of directors for the Biotechnology Industry Organization (BIO) and serves on BIO’s Emerging Companies Section Governing Board. Stuart Peltz received a Ph.D. from the McArdle Laboratory for Cancer Research at the University of Wisconsin.
current job
organization founded
Stuart Peltz
Allan Jacobson
Allan Jacobson, Ph.D. is a co-founder of PTC and has served as a member of the board of directors since the company's inception in 1998, and previously served as Chairman of our board of directors from 1998 to 2004. Since 2000, Dr. Jacobson has served as Chairman of the scientific advisory board. Since 1994, Dr. Jacobson has been the Chairman of the Department of Microbiology and Physiological Systems at the University of Massachusetts Medical School. In 1982, Dr. Jacobson co-founded Applied bioTechnology, Inc., a biotechnology company, and served as its chairman until its sale in 1991. From 1987 to 1990, Dr. Jacobson served as special limited partner at Euclid Partners, a venture capital firm. Dr. Jacobson received a Ph.D. from Brandeis University in 1971, has authored over 100 publications in the field of post-transcriptional control processes and is an elected member of the American Academy of Microbiology.
current job
organization founded
Allan Jacobson
Employee Profiles195
James Finnegan
Associate manager, infrastructure and network
Quintus Ngumah
Vice president and head of early clinical development
Michelle Durcholz
Manager, quality operations - training
Christopher Delagrange
Senior director, commercial development
Activity
Recent News29
The graph reveals the ratio (%) of positive news articles in a chosen time range